ORCHARD THERAPEUTICS PLC financial statements (2022 and earlier)

Company profile

Business Address 108 CANNON STREET
LONDON, EC4N 6EU
State of Incorp.
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:192325
Cash and cash equivalents5519
Other undisclosed cash, cash equivalents, and short-term investments137306
Receivables31
Inventory, net of allowances, customer advances and progress billings1 
Inventory1 
Prepaid expense5 
Other undisclosed current assets2323
Total current assets:224350
Noncurrent Assets
Operating lease, right-of-use asset3019
Property, plant and equipment58
Restricted cash and investments44
Other noncurrent assets194
Other undisclosed noncurrent assets 14
Total noncurrent assets:5749
TOTAL ASSETS:281399
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2831
Accounts payable912
Accrued liabilities76
Employee-related liabilities1212
Debt56
Other undisclosed current liabilities1919
Total current liabilities:5256
Noncurrent Liabilities
Long-term debt and lease obligation4440
Long-term debt, excluding current maturities2025
Operating lease, liability2415
Liabilities, other than long-term debt74
Other liabilities74
Total noncurrent liabilities:5144
Total liabilities:103100
Stockholders' equity
Stockholders' equity attributable to parent178299
Common stock1312
Additional paid in capital771738
Accumulated other comprehensive income02
Accumulated deficit(606)(454)
Total stockholders' equity:178299
TOTAL LIABILITIES AND EQUITY:281399

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
Revenues33
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)
Gross profit:22
Operating expenses(159)(175)
Operating loss:(157)(173)
Nonoperating income47
Investment income, nonoperating37
Other nonoperating income31
Interest and debt expense(2)(2)
Loss from continuing operations before equity method investments, income taxes:(155)(167)
Other undisclosed income from continuing operations before income taxes22
Loss from continuing operations before income taxes:(153)(166)
Income tax benefit12
Net loss available to common stockholders, diluted:(152)(163)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
Net loss:(152)(163)
Other comprehensive loss(2)(1)
Comprehensive loss, net of tax, attributable to parent:(154)(165)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: